Tylenol maker defeats lawsuit over labeling
Send a link to a friend
[August 29, 2024]
By Jonathan Stempel
NEW YORK (Reuters) - The maker of Tylenol defeated a lawsuit by
consumers who said they were deceived into overpaying for "Rapid
Release" gelcaps that did not relieve pain faster than cheaper tablets,
including those labeled Extra Strength and Regular Strength.
In a decision on Tuesday night, U.S. District Judge Andrew Carter in
Manhattan agreed with Kenvue that the federal Food, Drug, & Cosmetic Act
preempted the consumers' claims under New York state law.
Evie Collaza, the Bronx, New York resident who led the proposed class
action, had cited a 2018 study that found Rapid Release gelcaps took
longer than regular tablets -- 3.94 minutes versus 3.56 minutes -- to
dissolve by at least 80%.
But the judge said it would make no sense to ignore Food and Drug
Administration labeling rules for "immediate release" acetaminophen
products only because that agency did not use the exact words "rapid
release."
He said some judges have ruled similarly in lawsuits against the grocer
Albertsons, though one suggested in a lawsuit against pharmacy chain
Rite Aid that "immediate" and "rapid" were not synonymous.
"To hold that the FDA's regulation of acetaminophen dissolution rates
ought not control simply because a drug producer markets or prices
several of its qualifying 'immediate release' products in varying
manners would be to create an end-run around the FDCA’s express
preemption clause," Carter wrote.
[to top of second column]
|
Tylenol brand pain relief medicine is seen on display at the Safeway
store in Wheaton, Maryland February 13, 2015. REUTERS/Gary
Cameron/File Photo
Kenvue, based in Skillman, New
Jersey, was part of Johnson & Johnson before being spun off in
August 2023.
Lawyers for Collaza did not immediately respond to requests for
comment. Kenvue and its lawyers did not immediately respond to
similar requests.
The case is Collaza v Johnson & Johnson Consumer Inc, U.S. District
Court, Southern District of New York, No. 23-06030.
(Reporting by Jonathan Stempel in New York; Editing by Bill Berkrot)
[© 2024 Thomson Reuters. All rights reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|